Danaher (NYSE:DHR) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Danaher (NYSE:DHR) had its price target boosted by The Goldman Sachs Group from $265.00 to $270.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The firm presently has a “buy” rating on the conglomerate’s stock. The Goldman Sachs Group’s price objective indicates a potential upside of 13.63% from the company’s previous close.

Several other equities analysts have also weighed in on the company. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 price objective (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Redburn Partners set a $220.00 price objective on shares of Danaher in a research report on Wednesday, October 8th. Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 8th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a report on Thursday, December 18th. Twenty-one analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $252.09.

Danaher Stock Performance

NYSE:DHR traded up $3.29 during mid-day trading on Tuesday, hitting $237.62. The stock had a trading volume of 442,820 shares, compared to its average volume of 2,932,232. Danaher has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The company has a 50 day simple moving average of $229.17 and a 200-day simple moving average of $212.44. The stock has a market capitalization of $167.84 billion, a price-to-earnings ratio of 48.96, a P/E/G ratio of 4.20 and a beta of 0.89.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.71 earnings per share. On average, research analysts expect that Danaher will post 7.63 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 over the last quarter. Company insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Danaher

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new position in Danaher in the third quarter worth about $25,000. WFA of San Diego LLC purchased a new stake in Danaher in the second quarter worth about $26,000. Howard Hughes Medical Institute bought a new position in shares of Danaher in the second quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd bought a new position in Danaher in the 3rd quarter worth $27,000. Finally, TruNorth Capital Management LLC purchased a new stake in shares of Danaher during the third quarter worth about $28,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.